*BELITE BIO ANNOUNCES UK’S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY AGREES TO CONDITIONAL MARKETING AUTHORIZATION APPLICATION BASED ON INTERIM ANALYSIS RESULTS FOR THE TREATMENT OF STARGARDT DISEASE WITH TINLAREBANT
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 02-NOV-202514:00:00.137 GMT